FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1861-1863 December 17, 1998 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The EPIC Investigators PubMed Citation

To the Editor: Abciximab (ReoPro, Eli Lilly, Indianapolis, and Centocor, Malvern, Pa.), a new antiplatelet agent, is used during high-risk percutaneous transluminal coronary angioplasty (PTCA). In the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial, the use of an abciximab bolus was associated with major bleeding complications in 11 percent of patients.¹ No significant differences in the risk of major bleeding were observed among the three treatment groups in the Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade (EPILOG) study.² The incidence of major bleeding (3.8 percent) was lower in the c7E3 Fab . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Applegate, R. J., Sacrinty, M. T., Kutcher, M. A., Kahl, F. R., Gandhi, S. K., Santos, R. M., Little, W. C. (2008). Trends in Vascular Complications After Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention Via the Femoral Artery, 1998 to 2007. J Am Coll Cardiol Intv 1: 317-326 [Abstract] [Full Text]  
• Nikolsky, E., Mehran, R., Dangas, G., Fahy, M., Na, Y., Pocock, S. J., Lincoff, A. M., Stone, G. W. (2007). Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 28: 1936-1945 [Abstract] [Full Text]  
• Kalra, S., Bell, M. R., Rihal, C. S. (2001). Alveolar Hemorrhage as a Complication of Treatment With Abciximab. Chest 120: 126-131 [Abstract] [Full Text]